Global Oncology Based In-vivo CRO Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Indication;
Blood Cancer & Solid Tumors - Syngeneic Model, Patient-Derived Xenograft (PDX), & Xenograft, and Other.By Model;
Syngeneic, Xenograft, and Patient Derived Xenograft (PDX).By Geography;
North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).Introduction
Global Oncology Based In-vivo CRO Market (USD Million), 2021 - 2031
In the year 2024, the Global Oncology Based In-vivo CRO Market was valued at USD 995.19 million. The size of this market is expected to increase to USD 1,651.07 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 7.5%.
The global oncology-based in-vivo Contract Research Organization (CRO) market is experiencing significant growth, driven by the escalating burden of cancer worldwide. With cancer remaining one of the leading causes of morbidity and mortality, the need for innovative and effective treatments is paramount. In-vivo CROs play a crucial role in this context by providing comprehensive services for preclinical and clinical research, enabling pharmaceutical and biotechnology companies to accelerate the development of new cancer therapies. These organizations offer specialized expertise and infrastructure, which are essential for conducting complex in-vivo studies that form the backbone of oncology research.
Technological advancements have been a major catalyst in the growth of the in-vivo CRO market. Innovations in imaging techniques, genomics, and biomarker identification have significantly enhanced the precision and efficiency of in-vivo studies. These advancements not only improve the accuracy of cancer research but also reduce the time and cost associated with drug development. As a result, pharmaceutical companies are increasingly outsourcing their in-vivo research needs to CROs, leveraging their state-of-the-art technologies and specialized skills to gain a competitive edge in the oncology market.
Despite the promising growth prospects, the market faces several challenges that could impede its expansion. The high cost of conducting in-vivo studies, coupled with ethical concerns surrounding animal testing, presents significant hurdles. Additionally, stringent regulatory requirements and the complexity of obtaining approvals for in-vivo studies can slow down the research process. Moreover, the limited availability of skilled personnel capable of conducting sophisticated in-vivo studies further restricts market growth. Addressing these challenges is crucial for the sustained expansion of the oncology-based in-vivo CRO market.
Opportunities for growth in this market are abundant, particularly in emerging markets where healthcare infrastructure is rapidly developing. Increased collaborations and partnerships between pharmaceutical companies, academic institutions, and CROs can drive innovation and efficiency in research. The integration of advanced technologies such as artificial intelligence and big data analytics holds the potential to revolutionize in-vivo studies by providing deeper insights and accelerating the research process. Furthermore, ongoing government initiatives and funding dedicated to cancer research can provide additional support, fostering an environment conducive to the growth of oncology-based in-vivo CROs.
Global Oncology Based In-vivo CRO Market Recent Developments
-
In October 2022, Moderna, Inc., and Merck reported that Merck had exercised its option to develop and commercialize personalized cancer vaccine (PCV) jointly mRNA-4157/V940 under the terms of its existing Collaboration and License Agreement.
-
In March 2022, eTheRNA immunotherapies introduced a new Lipid Nanoparticle (LNP) formulation development and production service to support the discovery and early pre-clinical development of RNA-based therapeutics and vaccines.
Segment Analysis
The global oncology-based in-vivo CRO market, segmented by indication into blood cancer and solid tumors, is witnessing substantial growth driven by increasing cancer incidence and advancements in personalized medicine. For blood cancers and solid tumors, the use of various models such as syngeneic, patient-derived xenograft (PDX), and xenograft plays a crucial role. Syngeneic models, involving transplanting tumors from the same genetic background, are valuable for studying immune responses. PDX models, which involve implanting human tumor tissues into immunodeficient mice, are particularly significant for personalized medicine, providing a more accurate representation of human tumor biology. Traditional xenograft models, involving the transplantation of human cancer cells into mice, are widely used for drug efficacy studies.
By model type, the market is categorized into syngeneic, xenograft, and patient-derived xenograft (PDX). Syngeneic models are gaining traction due to their ability to mimic the tumor microenvironment and immune response. Xenograft models remain popular for their simplicity and cost-effectiveness, allowing high-throughput screening of anti-cancer drugs. PDX models, however, are increasingly preferred for their superior accuracy in replicating human tumor characteristics, which is critical for the development of targeted therapies. The growth in these models is supported by advancements in imaging and genetic tools, which enhance the reliability and applicability of in-vivo studies.
Geographically, the market is analyzed across North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America, with a forecast period from 2020 to 2030. North America dominates the market due to its advanced healthcare infrastructure, high R&D investment, and favorable regulatory environment. Europe follows, driven by significant government and private sector investments in cancer research. The Asia Pacific region is expected to witness the fastest growth, attributed to increasing cancer prevalence, rising healthcare expenditure, and expanding CRO services. Meanwhile, the Middle East and Africa, along with Latin America, present emerging opportunities due to improving healthcare systems and growing focus on cancer research.
The forecast from 2020 to 2030 indicates sustained market growth driven by technological advancements, increasing collaborations, and the development of novel cancer therapies. Government initiatives and funding for cancer research, particularly in emerging economies, are expected to boost the market further. Despite challenges such as high costs, ethical concerns, and regulatory hurdles, the market is poised for significant expansion. The continuous evolution of in-vivo models and integration of advanced technologies like AI and big data analytics are anticipated to enhance research capabilities and drive the oncology-based in-vivo CRO market forward.
Global Oncology Based In-vivo CRO Segment Analysis
In this report, the Global Oncology Based In-vivo CRO Market has been segmented by Indication, Model and Geography.
Global Oncology Based In-vivo CRO Market, Segmentation by Indication
The Global Oncology Based In-vivo CRO Market has been segmented by Indication into Blood cancer, Solid tumors and Other.
The global oncology-based in-vivo CRO market for blood cancer research is witnessing significant growth due to the increasing prevalence of hematologic malignancies and the demand for effective treatments. Syngeneic models, which use immunocompetent mice and same-strain tumor cells, are pivotal in studying immune responses and developing immunotherapies. These models are particularly valuable for blood cancers as they provide insights into the tumor microenvironment and immune interactions. Patient-derived xenografts (PDX) in blood cancer research involve implanting human cancer cells into immunodeficient mice, preserving the tumor's genetic makeup and heterogeneity. This approach aids in the evaluation of personalized therapies and drug efficacy, enhancing translational research.
For solid tumors, the syngeneic model is instrumental in understanding tumor-immune system interactions and testing new immunotherapies. Solid tumors, such as those in the breast, lung, and colon, benefit from these models as they replicate the complexity of the human immune system's response to cancer. Syngeneic models help in assessing the effectiveness of various immunotherapies and combination treatments, providing a robust platform for preclinical studies. PDX models for solid tumors are crucial for preserving the genetic diversity and heterogeneity of human cancers, allowing researchers to study drug responses in a more clinically relevant setting. This approach is particularly beneficial for cancers with high mutation rates and diverse genetic profiles.
Xenograft models, which involve transplanting human tumor cells into immunocompromised mice, remain a staple in oncology research for both blood cancers and solid tumors. These models enable the study of human tumor growth and metastasis in a controlled environment, facilitating the development and testing of anti-cancer drugs. Xenografts are widely used due to their ability to provide consistent and reproducible results, making them essential for early-stage drug development and screening. The versatility of xenograft models allows for their application across various cancer types, providing a broad platform for preclinical evaluation.
Other models in the global oncology-based in-vivo CRO market include genetically engineered mouse models (GEMMs) and orthotopic models, which offer additional insights into cancer biology and treatment. GEMMs are designed to mimic human cancer genetics closely, providing a deeper understanding of tumor development and progression. Orthotopic models involve implanting tumor cells into the original organ site, offering a more accurate representation of tumor behavior and metastatic patterns. These advanced models complement syngeneic, PDX, and xenograft models, enhancing the overall capability of in-vivo CROs to conduct comprehensive cancer research and accelerate the development of new therapeutics.
Global Oncology Based In-vivo CRO Market, Segmentation by Model
The Global Oncology Based In-vivo CRO Market has been segmented by Model into Syngeneic, Xenograft and Patient Derived Xenograft (PDX).
In the global oncology-based in-vivo CRO market, the syngeneic model is significant due to its ability to provide a comprehensive understanding of tumor-host interactions in an immunocompetent setting. Syngeneic models involve the transplantation of tumor cells from the same genetic background, typically mice, which allows researchers to study immune responses and evaluate the efficacy of immunotherapies. These models are particularly useful in the development of immune checkpoint inhibitors and other immuno-oncology treatments, offering insights into how the immune system interacts with cancer cells in a controlled environment.
Xenograft models, on the other hand, involve the transplantation of human cancer cells into immunocompromised mice. This model is essential for studying human tumor biology in a living organism and for assessing the therapeutic potential of new cancer drugs. Xenografts are widely used because they can closely mimic the behavior of human tumors, providing valuable data on tumor growth, metastasis, and response to treatment. The primary advantage of xenograft models lies in their ability to facilitate the testing of human-specific cancer therapies, making them a cornerstone in preclinical oncology research.
Patient-derived xenograft (PDX) models take this approach a step further by implanting tumor tissues directly from cancer patients into immunodeficient mice. PDX models preserve the histological and genetic characteristics of the original patient tumors, offering a more accurate representation of human cancer. This model is particularly advantageous for personalized medicine, as it allows for the testing of individualized treatment regimens based on the patient's specific tumor profile. PDX models are highly valued for their predictive accuracy and are increasingly used in the development of targeted therapies and in studying drug resistance mechanisms.
Together, these models contribute significantly to the oncology-based in-vivo CRO market by providing a range of tools to study cancer biology and test new treatments. The syngeneic model offers insights into immunotherapy within an immune-competent system, xenografts provide a reliable method for testing human-specific therapies, and PDX models offer a high-fidelity representation of patient tumors for personalized medicine. These diverse models enable CROs to conduct comprehensive preclinical studies, accelerating the development of effective cancer therapies and improving the translational potential of preclinical findings to clinical applications.
Global Oncology Based In-vivo CRO Market, Segmentation by Geography
In this report, the Global Oncology Based In-vivo CRO Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global Oncology Based In-vivo CRO Market Share (%), by Geographical Region, 2024
The Global Oncology Based In-vivo CRO Market is projected to experience significant growth across various geographical regions between 2020 and 2030. In North America, the market is expected to be driven by the high prevalence of cancer, advanced healthcare infrastructure, and substantial investment in research and development. The presence of major pharmaceutical and biotechnology companies, along with favorable regulatory policies, further supports market expansion in this region. Additionally, North America's strong emphasis on technological advancements and personalized medicine fuels the demand for in-vivo CRO services in oncology research.
Europe is anticipated to witness robust growth in the oncology-based in-vivo CRO market due to the increasing cancer burden and the region's commitment to medical research and innovation. The European Union's support for cancer research, along with various government initiatives and funding programs, plays a crucial role in propelling market growth. Moreover, the presence of well-established healthcare systems and a growing focus on precision medicine contribute to the rising demand for in-vivo CRO services in oncology. Collaboration between academic institutions, research organizations, and CROs is also a significant factor driving the market in Europe.
In the Asia Pacific region, the oncology-based in-vivo CRO market is expected to expand rapidly due to the increasing incidence of cancer and the growing emphasis on healthcare infrastructure development. Countries like China, Japan, and India are becoming key players in the market, driven by government support, rising healthcare expenditure, and an increasing number of clinical trials. The region's cost-effective research capabilities and the availability of skilled professionals further attract global pharmaceutical companies to outsource their in-vivo oncology studies to Asia Pacific CROs. This trend is likely to continue, enhancing the region's market growth during the forecast period.
The Middle East and Africa, along with Latin America, are also projected to see growth in the oncology-based in-vivo CRO market, albeit at a slower pace compared to other regions. In the Middle East and Africa, market growth is supported by improving healthcare infrastructure, rising awareness about cancer, and government initiatives aimed at boosting research activities. Latin America benefits from a growing focus on cancer research, increasing investments in healthcare, and collaborations with international research organizations. Both regions are expected to gradually enhance their contributions to the global oncology-based in-vivo CRO market from 2020 to 2030.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global Oncology Based In-vivo CRO Market. These factors include; Market Drivers, Restraints and Opportunities.
Drivers, Restraints and Opportunity
Drivers:
- Pharmaceutical R&D Investment
- Regulatory Support and Approvals
-
Growth in Personalized Medicine-The growth in personalized medicine is significantly influencing the global oncology-based in-vivo CRO market. Personalized medicine involves tailoring medical treatments to the individual characteristics of each patient, which requires a deep understanding of the genetic, environmental, and lifestyle factors that influence health and disease. In oncology, this approach is particularly crucial due to the complex and heterogeneous nature of cancer. As a result, there is an increased need for in-vivo studies that can provide the detailed insights required to develop these personalized treatments, driving demand for specialized CRO services.
In-vivo CROs are uniquely positioned to support the development of personalized oncology treatments. These organizations have the expertise and infrastructure to conduct complex in-vivo studies that are essential for understanding the efficacy and safety of personalized therapies. This includes the ability to create and manage diverse animal models that mimic the genetic and phenotypic variability seen in human cancers. By leveraging these capabilities, CROs can help pharmaceutical companies and research institutions accelerate the development of targeted therapies, which are a cornerstone of personalized medicine.
The rise of personalized medicine is also leading to increased collaboration between CROs, pharmaceutical companies, and academic institutions. These partnerships are essential for integrating the latest scientific advancements and technological innovations into the research and development process. CROs play a critical role in these collaborations by providing the necessary in-vivo expertise and resources. This collaborative approach not only enhances the quality and efficiency of research but also helps in overcoming some of the challenges associated with personalized medicine, such as the need for extensive biomarker validation and the development of companion diagnostics.
The regulatory environment is increasingly supportive of personalized medicine, which benefits the oncology-based in-vivo CRO market. Regulatory agencies are recognizing the importance of personalized approaches in improving patient outcomes and are thus providing frameworks that facilitate the approval of personalized therapies. This regulatory support is encouraging more investment in personalized medicine research, leading to a higher volume of in-vivo studies. Consequently, in-vivo CROs are experiencing growing demand for their services, positioning them as essential players in the advancement of personalized oncology treatments.
Restraints:
- Regulatory Hurdles
- Limited Availability of Skilled Personnel
-
Variability in Animal Models-Variability in animal models is a significant challenge in the global oncology-based in-vivo CRO market. These models are crucial for preclinical testing of new cancer therapies, but the inherent differences between animals and humans can lead to variability in study outcomes. This variability can impact the predictive value of animal models for human responses, making it difficult to translate findings from animal studies directly to clinical settings. As a result, there is a constant need to refine and improve animal models to ensure they more accurately mimic human cancer biology.
One major source of variability is the genetic and physiological differences between species. Even within the same species, variations in genetics, age, sex, and overall health can influence the way animals respond to cancer therapies. These differences can lead to inconsistent results, making it challenging to draw definitive conclusions from in-vivo studies. To mitigate this, researchers often use genetically modified animals or create specific strains that closely resemble human cancer conditions, although this approach does not entirely eliminate variability.
Another issue is the environmental factors that can affect animal models. Variables such as diet, housing conditions, and stress levels can significantly impact the outcomes of in-vivo studies. Standardizing these conditions is crucial, but achieving perfect consistency is difficult in practice. These environmental differences can introduce additional variability, complicating the interpretation of results. Consequently, CROs must implement stringent controls and protocols to minimize these influences and enhance the reliability of their studies.
Despite these challenges, ongoing advancements in technology and methodology are helping to reduce the impact of variability in animal models. Improved imaging techniques, better understanding of cancer biology, and the development of more sophisticated models, such as patient-derived xenografts, are enhancing the predictive power of in-vivo studies. By continuing to refine these models and incorporate new technologies, the in-vivo CRO market can improve the accuracy and reliability of preclinical oncology research, ultimately leading to more effective and safe cancer therapies.
Opportunities:
- Technological Integration
- Development of Novel Therapeutics
-
Government Initiatives and Funding-Government initiatives and funding are playing a crucial role in advancing the global oncology-based in-vivo CRO market. Many governments are increasing their investments in cancer research, recognizing the rising incidence of cancer worldwide and the need for innovative treatments. These investments often come in the form of grants and subsidies aimed at boosting research and development activities within the oncology sector. By providing financial support, governments help reduce the burden of research costs for pharmaceutical companies and CROs, enabling them to undertake more comprehensive and ambitious projects.
Several government programs focus on fostering collaboration between public and private sectors, including academic institutions, healthcare organizations, and biopharmaceutical companies. These collaborations are designed to leverage collective expertise and resources to accelerate the development of new cancer therapies. For instance, initiatives such as public-private partnerships can facilitate access to advanced technologies and infrastructure that individual organizations might find challenging to acquire independently. This collaborative approach not only enhances research capabilities but also improves the overall efficiency and effectiveness of oncology studies.
Regulatory agencies are also contributing to the growth of the oncology-based in-vivo CRO market by streamlining approval processes for clinical trials and new drugs. Governments are implementing policies that support faster and more flexible regulatory pathways, which can significantly reduce the time and cost associated with bringing new cancer treatments to market. This regulatory support is particularly beneficial for CROs, as it allows them to navigate the complex approval landscape more efficiently, ultimately accelerating the pace of innovation in cancer research.
In addition to direct financial support and regulatory facilitation, some governments are investing in infrastructure and capacity-building initiatives. These efforts include establishing specialized research centers, enhancing laboratory facilities, and providing training programs to develop a skilled workforce in oncology research. By creating a robust infrastructure and skilled talent pool, governments are laying the groundwork for sustained growth and advancement in the oncology-based in-vivo CRO market. These comprehensive initiatives and funding strategies underscore the critical role of government support in driving forward the fight against cancer and improving patient outcomes globally.
Competitive Landscape Analysis
Key players in Global Oncology Based In-vivo CRO Market include:
- Charles River Laboratory (CRL)
- ICON Plc
- Covance
- Eurofins Scientific
- Taconic Biosciences
- Crown Bioscience
- Toxikon, Inc.
- WuXi AppTec
- EVOTEC
- The Jackson Laboratory
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Model
- Market Snapshot, By Region
- Global Oncology Based In-vivo CRO Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Pharmaceutical R&D Investment
- Regulatory Support and Approvals
- Growth in Personalized Medicine
- Restraints
- Regulatory Hurdles
- Limited Availability of Skilled Personnel
- Variability in Animal Models
- Opportunities
- Technological Integration
- Development of Novel Therapeutics
- Government Initiatives and Funding
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global Oncology Based In-vivo CRO Market, By Indication, 2021- 2031(USD Million)
- Blood cancer
- Solid tumors
- Syngeneic model
- Patient-Derived Xenograft (PDX)
- Xenograft
- Other
- Global Oncology Based In-vivo CRO Market, By Model, 2021- 2031(USD Million)
- Syngeneic
- Xenograft
- Patient Derived Xenograft (PDX)
- Global Oncology Based In-vivo CRO Market, By Geography, 2021- 2031(USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global Oncology Based In-vivo CRO Market, By Indication, 2021- 2031(USD Million)
- Competitive Landscape
- Company Profiles
- Charles River Laboratory (CRL)
- ICON Plc
- Covance
- Eurofins Scientific
- Taconic Biosciences
- Crown Bioscience
- Toxikon, Inc.
- WuXi AppTec
- EVOTEC
- The Jackson Laboratory
- Company Profiles
- Analyst Views
- Future Outlook of the Market